Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes
Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
Many people with type 2 diabetes cannot maintain target blood glucose levels when taking a
single oral drug. The purpose of this study is to assess the safety and effectiveness of
vildagliptin, an unapproved drug, in lowering overall blood glucose levels when added to
pioglitazone in people with type 2 diabetes not at target blood glucose levels on either
pioglitazone or rosiglitazone alone.